Ligand to Participate in Two Upcoming Investor Conferences

SAN DIEGO–(BUSINESS WIRE)– Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that
company executives are scheduled to participate in the following
upcoming investor conferences:

• 14^th Annual Craig-Hallum Institutional Investor Conference
  in Minneapolis. Conference takes place on Wednesday, May 31, 2017 with
  one-on-one meetings only. John Higgins, CEO; Matt Foehr, President and
  COO; and Matt Korenberg, CFO, will attend for Ligand.
• Jefferies Healthcare Conference in New York City. Presentation takes
  place on Thursday, June 8, 2017 at 4:00 p.m. Eastern time (1:00 p.m.
  Pacific time). John Higgins, CEO; Matt Foehr, President and COO; and
  Matt Korenberg, CFO, will attend for Ligand.

A live webcast of the presentation will be available on Ligand’s website
at www.ligand.com.
A replay of the presentation will be archived on the website for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring
technologies that help pharmaceutical companies discover and develop
medicines. Our business model creates value for stockholders by
providing a diversified portfolio of biotech and pharmaceutical product
revenue streams that are supported by an efficient and low corporate
cost structure. Our goal is to offer investors an opportunity to
participate in the promise of the biotech industry in a profitable,
diversified and lower-risk business than a typical biotech company. Our
business model is based on doing what we do best: drug discovery,
early-stage drug development, product reformulation and partnering. We
partner with other pharmaceutical companies to leverage what they do
best (late-stage development, regulatory management and
commercialization) to ultimately generate our revenue. Ligand’s Captisol^®
platform technology is a patent-protected, chemically modified
cyclodextrin with a structure designed to optimize the solubility and
stability of drugs. OmniAb^® is a patent-protected transgenic
animal platform used in the discovery of fully human mono- and
bispecific therapeutic antibodies. Ligand has established multiple
alliances, licenses and other business relationships with the world’s
leading pharmaceutical companies including Novartis, Amgen, Merck,
Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand_LGND.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170522005420/en/